MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from pipe, net
$27,384K
Proceeds from
convertible note
$17,898K
Proceeds from loan
payable, net of debt...
$693K
Proceeds from stock
option exercises
$206K
Net cash provided by
financing activities
$45,336K
Canceled cashflow
$845K
Net increase in cash
and cash...
$17,510K
Canceled cashflow
$27,826K
Payment of loan payable,
net of debt discount
$845K
Change in fair value of
convertible note
-$14,984K
Accrued expenses
$6,163K
Stock-based compensation
$5,461K
Accretion of interest for
royalty obligations
$2,397K
Contingent consideration
$2,200K
Inventory
-$1,778K
Amortization of intangible
assets
$1,556K
Accounts payable
$1,356K
Inventory write-off
$1,055K
Depreciation of property and
equipment
$729K
Operating lease
right-of-use assets
-$345K
Impairment of intangible
assets
$285K
Amortization of debt discount
$259K
Lease amortization
expense
$74K
Other assets and
liabilities
-$35K
Acquisition of lnhc, inc
$2,761K
Net cash used in
operating activities
-$22,590K
Net cash used in
investing activities
-$5,236K
Canceled cashflow
$38,677K
Canceled cashflow
$2,761K
Net loss
-$43,319K
Assets
acquisition-Xepi Acquisition
$6,080K
Accounts receivable
$8,810K
Deferred income tax
$7,387K
Prepaid expenses
$880K
Deferred revenue
-$589K
Operating lease
liabilities
-$282K
Assets
acquisition-XEGLYZEAsset Purchase...
$1,818K
Purchases of property and
equipment
$99K
Back
Back
Cash Flow
source: myfinsight.com
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)